Rhizen Pharmaceuticals SA Company
Rhizen is a clinical-stage biopharmaceutical company focused on discovery and development of innovative, small molecule drugs that target signal transduction networks and ion channels for the treatment of cancer, inflammation, autoimmune diseases and metabolic disorders.
Industry:
Genomic and Epigenominc Instabillity
Headquarters:
Switzerland
Register and Claim Ownership